News | Clinical Decision Support | June 16, 2020

Philips and MD Anderson Collaborate to Provide Oncologists with Evidence-based Therapy, Clinical Trial Guidance

Philips connects oncologists and pathologists around the world to MD Anderson’s Precision Oncology Decision Support (PODS) system of actionable clinical information

Philips connects oncologists and pathologists around the world to MD Anderson’s Precision Oncology Decision Support (PODS) system of actionable clinical information

Image courtesy of Philips

June 16, 2020 — Philips and The University of Texas MD Anderson Cancer Center announced a collaboration to provide oncologists with evidence-based therapy and clinical trial guidance through Philips’ oncology informatics solutions and MD Anderson’s Precision Oncology Decision Support (PODS) system. This collaboration will allow physicians around the world to personalize therapy based on the patient’s genomic profile, with the aim of improving patient care.

MD Anderson developed the PODS system as an evidence-based tool to facilitate therapeutic decision-making at the point of care. The system provides actionable clinical information, including approved therapies and available clinical trials, based upon genetic alterations within the tumor. Through the Philips solutions, clinicians receive a unified view of therapies and clinical trials in the context of their patient’s unique tumor, helping them make an evidence-based decision for their patient’s treatment.

“We developed PODS to enable physicians to better understand and act on genetic variations within each patient’s tumor, making it easier to provide the best treatments possible,” said Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics at MD Anderson. “Through our collaboration with Philips, we hope to share our clinical experience with physicians around the world and contribute to improving care for patients globally.”

Today, pathologists and oncologists are faced with the challenges of keeping abreast of the increasing number of therapy options and the rapid advances in genomic testing, the molecular findings of which require increasingly specialized expertise to interpret. The growing amount of evidence for newly approved targeted and immune-oncology therapies necessitates solutions to simplify the complexity. Philips and MD Anderson aim to help pathologists and oncologists serve their patients and provide them with therapeutic options and relevant clinical trials based on tumor markers.

“Driven by the latest therapy breakthroughs, a deeper understanding of cancer biology and an increasing number of clinical trials, oncology practices can provide more options than ever for many patients,” said Louis Culot, General Manager of Oncology Informatics at Philips. “Broadening our long-standing collaboration with MD Anderson, Precision Oncology Decision Support becomes available to physicians through the Philips oncology informatics solution, providing the latest actionable information that supports their confident clinical decision-making.“

For more information: www.philips.com

 

Related Content

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association's...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with...
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann
Now, researchers using magnetic resonance imaging (MRI) have found potential brain biomarkers of PTSD in people with traumatic brain injury (TBI).
News | Magnetic Resonance Imaging (MRI) | December 31, 2020
December 31, 2020 — Posttraumatic stress disorder (...
Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep

Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep (cool colors in the left columns), are reactivated when regaining a con-nected state upon emergence from anesthesia (warm colors in the right columns). Graphic courtesy of University of Turku

News | PET Imaging | December 30, 2020
December 30, 2020 — What happens in the brain when our conscious awareness fades during general anesthesia and normal